News
Three studies presented today at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether ...
British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs to curb their off-label use for weight ...
Three studies presented today at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether ...
New and disturbing concerns about fake GLP-1 drugs are cited in a letter sent to the FDA by Tennessee officials, including Sen. Marsha Blackburn.
Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.
Improving Global Outcomes (KDIGO) group has updated chronic kidney disease treatment guidelines to help slow disease progression in adults. A JAMA article published Wednesday summarized the revised ...
Presented by AstraZeneca{beacon} Health Care Health Care The Big Story CMS targets hospitals with site-neutral drug ruleThe ...
Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.
For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...
New research published Tuesday concludes that the rising rate of extreme childhood obesity—well above the usual BMI ...
In what Science magazine has dubbed “Novo Nordisk’s Canadian Mistake,” Ozempic is soon to come off patent in Canada, opening ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results